GI Innovation Receives FDA Fast Track Designation for GI-102 Melanoma Therapy
Key Insights
Korean biotech GI Innovation (search) has secured FDA Fast Track Designation for GI-102, a next-generation immuno-oncology therapy targeting advanced or metastatic melanoma (search).
Phase 1 trial results showed GI-102 achieved a 25% objective response rate and 83% disease control rate in 14 patients previously treated with other immunotherapies.
The company is advancing Phase 2 trials combining GI-102 with Merck (search)'s Keytruda, with the fast track status potentially accelerating approval to as little as six months.
Korean biotech company GI Innovation (search) announced it has received Fast Track Designation from the US Food and Drug Administration for GI-102, its next-generation immuno-oncology therapy targeting advanced or metastatic melanoma (search). The designation represents a significant regulatory milestone for the company's lead asset in addressing an aggressive cancer with limited treatment options.
FDA Fast Track Benefits
The FDA's fast track program is designed to speed the review of treatments for serious conditions with limited options. The designation allows for closer consultation with the agency, rolling data submissions and potential benefits such as priority review or accelerated approval, which can shorten the process to as little as six months.
Growing Medical Need
Melanoma (search), the most aggressive type of skin cancer (search), is on the rise worldwide. According to the journal Jama Dermatology, the number of patients has been steadily increasing, heightening the need for new therapies. "Worldwide, metastatic melanoma (search) patients face limited treatment options once immunotherapies fail," said Jang Myung-ho, CEO of GI Innovation (search).
Clinical Trial Results
GI-102, delivered as a subcutaneous injection, showed encouraging results in a Phase 1 trial involving 14 patients who had previously been treated with other immunotherapies. The study reported an objective response rate of 25 percent and a disease control rate of 83 percent, both significantly higher than the approved standard therapy Opdualag.
Development Pipeline
The company is now running Phase 2 trials combining GI-102 with Merck (search)'s Keytruda, and additional studies with antibody drug conjugates in the US and Korea. "This fast track designation increases the possibility of commercialization and brings us closer to our goal of accelerated approval," Jang noted.